(SUMM) Summit Corporation

Summit Corporation plc       
('Summit' or 'the Company')

SUMMIT SECURES $1.5M AGREEMENT WITH US DMD ORGANISATIONS

• Proceeds to fully fund new Phase I clinical trial of Summit's potential
  first-in-class DMD drug SMT C1100  

• SMT C1100 has the potential to treat all DMD patients 

Oxford, UK, 19 December 2011, Summit (AIM: SUMM), a UK drug discovery company, announces that it has entered into agreements collectively worth $1.5 million with several US-based organisations for its utrophin upregulation drug candidate SMT C1100 for the treatment of the fatal neuromuscular disease Duchenne Muscular Dystrophy ('DMD').  The funding comprises of $750,000 from the Muscular Dystrophy Association ('MDA'), $250,000 from Parent Project Muscular Dystrophy ('PPMD') and $500,000 from a group of four independent Duchenne foundations spanning the US: Charley's Fund, Cure Duchenne, Foundation to Eradicate Duchenne and the Nash Avery Foundation.  Under the terms of the agreements, Summit retains full ownership of this asset.

The funding provided by these agreements will enable Summit to manufacture a new formulation of SMT C1100 and conduct a Phase I clinical trial in healthy volunteers.  The trial will evaluate if the new formulation can provide consistent levels of the drug in the blood that non-clinical efficacy studies predicted would be required to confer therapeutic benefit in DMD Patients.  Upregulation (increasing) of utrophin protein levels has the potential to treat all DMD patients and Summit has ensured the formulation selected will be appropriate for use by all patient age-groups.  The work will be conducted by Summit.

"A long-time champion for utrophin upregulation as a promising therapeutic strategy for treating Duchenne Muscular Dystrophy, MDA is pleased Summit soon will begin testing a new formulation of SMT C1100 in a human clinical trial," saidValerie Cwik, M.D. Executive Vice President Research and Medical Director for the Muscular Dystrophy Association.  "This is a vital step toward determining whether this strategy will have a beneficial effect in individuals with DMD."

Barry Price, PhD, Executive Chairman of Summit commented: "Summit is delighted to receive broad support from the community of foundations focused on DMD.  Their generous funding will allow a new clinical study to be conducted on SMT C1100, a drug discovered and developed by our scientists, which we believe has the potential to treat all DMD patients and provide benefit for them and their families.  These agreements ensure that one of Summit's core assets will advance through to a key development milestone that has the potential to add considerable value to the programme in the near-term."

He added: "Summit is especially pleased to conclude this deal when set against the uncertainties of an increasingly austere and challenging global environment for a number of sectors including the life sciences industry.  The Board remains confident about signing further agreements, but recognises that global and market uncertainties reduce its ability to be precise on the timing of deals from on-going confidential discussions with third parties."

- END -

For more information, please contact:

Notes to Editors

About Duchenne Muscular Dystrophy
Duchenne Muscular Dystrophy is a fatal genetic neuromuscular disorder that affects 1 in 3,500 boys with an estimated patient population of 50,000 in the developed world.  The disease is caused by mutations in the gene required to make dystrophin, a protein which maintains the integrity and healthy function of skeletal muscles.  One in three new DMD cases is due to a spontaneous mutation where there is no familial history of the disease.  The progressive muscle wasting begins in early childhood and typically leads to death in the twenties due to cardiac and respiratory failure.  Currently there is no cure for DMD.

About Utrophin Upregulation
Utrophin is a naturally occurring protein that has a similar function to dystrophin.  Utrophin is produced during foetal development but its production is switched off in adults.  If utrophin production could be maintained, it could act as a substitute for the missing dystrophin to maintain the healthy function of muscles.  One method of turning utrophin production back on is through pharmacological means.  Utrophin upregulation will be beneficial to all DMD patients regardless of their specific genetic mutation and is also expected to be complimentary to other therapeutic approaches in development.

About Summit
Summit is an Oxford, UK based drug discovery Company with an innovative Seglin(TM) technology platform for the discovery of new medicines and a portfolio of drug programme assets.  Seglin(TM) technology is using new chemistry to access biological drug targets that cannot be exploited by conventional drug discovery approaches and it is expected to have broad use in major disease areas.  Summit's programme portfolio consists of a number of drug programmes targeting high-value areas of unmet medical need including Duchenne Muscular Dystrophy and C. difficile infection.

Summit is listed on the AIM market of the London Stock Exchange and trades under the ticker symbol SUMM.  Further information is available at www.summitplc.com.

About Muscular Dystrophy Association
MDA is the non-profit agency dedicated to curing muscular dystrophy, ALS and related diseases by funding worldwide research.  The Association also provides comprehensive healthcare and support services, advocacy and education.

Long the world's leading non-governmental funder of muscular dystrophy research and health care services to affected individuals, MDA has played a pioneering role in utrophin-related research since 1996 (investing nearly $16 million to help develop this promising therapeutic pathway).   Presently, MDA active grants include 102 focused on Duchenne Muscular Dystrophy, representing a multi-year investment of close to $35 million.

In addition to annually funding some 300 research teams worldwide, MDA maintains a national network of some 200 hospital-affiliated clinics; facilitates hundreds of support groups for families affected by neuromuscular diseases; and provides extraordinary local summer camp opportunities for thousands of youngsters fighting progressive muscle diseases.  Known globally for its Labor Day Telethon, MDA is the first non-profit to receive a Lifetime Achievement Award from the American Medical Association "for significant and lasting contributions to the health and welfare of humanity."  To learn more visit www.mda.org.

About Parent Project Muscular Dystrophy
Duchenne is a fatal genetic disorder that slowly robs young men of their muscle strength. Parent Project Muscular Dystrophy's  mission is to end Duchenne.

We invest deeply in treatments for this generation of young men affected by Duchenne and in research that will benefit future generations. We advocate in Washington, DC, and have secured hundreds of millions of dollars in funding. We demand optimal care, and we strengthen, unite, and educate the global Duchenne community.

Everything we do-and everything we have done since our founding in 1994-helps boys with Duchenne live longer, stronger lives. We will not rest until every young man has a treatment to end Duchenne. Go to www.ParentProjectMD.org for more information or to learn how you can support our efforts and help families affected by Duchenne.

About Charley's Fund, Cure Duchenne, Foundation to Eradicate Duchenne,
and Nash Avery Foundation
Charley's Fund, Cure Duchenne, Foundation to Eradicate Duchenne, and Nash Avery Foundation are independent organisations devoted to developing treatments for Duchenne muscular dystrophy.   These groups, founded by parents of children with Duchenne, support the most promising research projects aimed at treating and curing the disease.

www.charleysfund.org
www.cureduchenne.org
www.duchennemd.org
www.nashaveryfoundation.org

Forward Looking Statements
This document contains "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as "anticipates", "intends", "plans", "seeks", "believes", "estimates", "expects" and similar references to future periods, or by the inclusion of forecasts or projections. Forward-looking statements are based on the Company's current expectations and assumptions regarding our business, the economy and other future conditions. Because forward-looking statements relate to the future, by their nature, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. The Company's actual results may differ materially from those contemplated by the forward-looking statements. The Company cautions you therefore that you should not rely on any of these forward-looking statements as statements of historical fact or as guarantees or assurances of future performance. Important factors that could cause actual results to differ materially from those in the forward-looking statements and regional, national, global political, economic, business, competitive, market and regulatory conditions.

More

Summit Corporation plc
('Summit' or 'the Company')

SMT C1100 RECEIVES ORPHAN DRUG STATUS FROM THE US FDA FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY

Oxford, UK, 24 November 2011, Summit (AIM: SUMM), a UK drug discovery company, is pleased to announce that the United States Food &  Drug Administration ('the US FDA') has granted orphan drug status to the clinical candidate SMT C1100 for the treatment of Duchenne Muscular Dystrophy ('DMD'), a fatal genetic neuromuscular disorder for which there is currently no cure.  The European Medicines Agency had granted SMT C1100 orphan drug status in December 2008.

Commenting on the news, Barry Price, PhD, Executive Chairman of Summit said:
"We are pleased the US FDA has designated SMT C1100 as an orphan drug for DMD as this recognises its potential to treat a major unmet medical need.  Our clinical candidate has now been granted orphan drug status both in Europe and the US, and this status will provide additional regulatory support and various commercial benefits including extended periods of market exclusivity.

"Summit believes that SMT C1100 can become a first-in-class treatment for DMD and it is our intention to commence a clinical study that will evaluate a new formulation of this drug that will benefit all patients with this fatal disease."

About Orphan Drug Designation
An orphan drug is a pharmaceutical agent that has been developed specifically to treat a rare medical condition, the condition itself being referred to as an orphan disease. The US Orphan Drug Act and European Orphan legislation are designed to assist and encourage companies in the development of urgently needed drugs for the treatment of rare diseases.  Orphan drug designation has a number of benefits including a valuable seven-year period of market exclusivity in the US following approval.  In Europe, a ten-year period of exclusivity is provided.  Orphan products can also expect to receive additional regulatory support, reduced fees and accelerated approval.  Further information about orphan drug designation can be found on the FDA's website, www.fda.com/oprhan.

About DMD and SMT C1100
DMD is caused by the absence of a protein called dystrophin which results in the degeneration of all skeletal and other vital muscles such as the heart.  There is no cure for DMD with the only available treatments being steroids that provide symptomatic relief.

SMT C1100 is a small molecule drug that works by increasing (upregulating) production of a similar, naturally occurring protein called utrophin to replace the missing dystrophin.  Summit recently published compelling preclinical data showing SMT C1100 can increase utrophin production to restore and maintain healthy muscle function.  A major advantage of utrophin upregulation is it will benefit all patients with DMD regardless of their specific genetic mutation and is expected to be complementary with other therapeutic approaches currently in development.

- END -

For more information, please contact:

Notes to Editors

About Summit
Summit is an Oxford, UK based drug discovery company with an innovative technology platform called Seglins for the discovery of new medicines, a portfolio of drug programme assets and a commercial strategy of signing multiple early-stage deals.

Seglin(TM) technology is using new chemistry to access biological drug targets that cannot be exploited by conventional drug discovery approaches.  Summit's internal research is currently focussed in high-value therapy areas and the Company will further exploit the technology's wider potential through strategic alliances.  Summit's programme portfolio consists of a number of drug programmes targeting high-value areas of unmet medical need including Duchenne Muscular Dystrophy and C. difficile infection.

Summit's commercial strategy focuses on signing multiple early-stage drug programme and technology platform deals that generate upfront cash, transfer development costs from the Company, and retain valuable upside potential.

Summit is listed on the AIM market of the London Stock Exchange and trades under the ticker symbol SUMM.  Further information is available at www.summitplc.com.

 Forward Looking Statements
This document contains "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as "anticipates", "intends", "plans", "seeks", "believes", "estimates", "expects" and similar references to future periods, or by the inclusion of forecasts or projections. Forward-looking statements are based on the Company's current expectations and assumptions regarding our business, the economy and other future conditions. Because forward-looking statements relate to the future, by their nature, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. The Company's actual results may differ materially from those contemplated by the forward-looking statements. The Company cautions you therefore that you should not rely on any of these forward-looking statements as statements of historical fact or as guarantees or assurances of future performance. Important factors that could cause actual results to differ materially from those in the forward-looking statements and regional, national, global political, economic, business, competitive, market and regulatory conditions.

More

Summit Corporation plc
("Summit" or "the Company")


APPOINTMENT OF HYBRIDAN AS JOINT BROKER

Oxford, UK, 1 November 2011, Summit (AIM: SUMM), a UK drug discovery company, is
pleased to announce the appointment of Hybridan LLP as joint broker alongside
its existing nominated adviser and broker, Singer Capital Markets Limited. The
appointment is with immediate effect.

- END -

For more information, please contact:

Summit
Barry Price, PhD,
Richard Pye, PhD Tel: +44 (0)1235 443 951


Singer Capital Markets
(Nominated Adviser and Joint broker)
Shaun Dobson / Claes Spång Tel: +44 (0)203 205 7500


Hybridan LLP
(Joint broker)
Claire Louise Noyce Tel: +44 (0)207 947 4004


Peckwater PR
(Financial public relations) Tel: +44 (0)7879 458 364
Tarquin Edwards tarquin.edwards@peckwaterpr.co.uk



Notes to Editors

About Summit
Summit is an Oxford, UK based drug discovery company with an innovative
technology platform called Seglins for the discovery of new medicines, a
portfolio of drug programme assets and a commercial strategy of signing multiple
early-stage deals.

Seglin(TM) technology is using new chemistry to access biological drug targets
that cannot be exploited by conventional drug discovery approaches.  Summit's
internal research is currently focussed in high-value therapy areas and the
Company will further exploit the technology's wider potential through strategic
alliances.  Summit's programme portfolio consists of a number of drug programmes
targeting high-value areas of unmet medical need including Duchenne Muscular
Dystrophy and C. difficile infection.

Summit's commercial strategy focuses on signing multiple early-stage drug
programme and technology platform deals that generate upfront cash, transfer
development costs from the Company, and retain valuable upside potential.

Summit is listed on the AIM market of the London Stock Exchange and trades under
the ticker symbol SUMM.  Further information is available at  www.summitplc.com.


 Forward Looking Statements
This document contains "forward-looking statements" within the meaning of the
U.S. Private Securities Litigation Reform Act of 1995. Forward-looking
statements can be identified by words such as "anticipates", "intends", "plans",
"seeks", "believes", "estimates", "expects" and similar references to future
periods, or by the inclusion of forecasts or projections. Forward-looking
statements are based on the Company's current expectations and assumptions
regarding our business, the economy and other future conditions. Because
forward-looking statements relate to the future, by their nature, they are
subject to inherent uncertainties, risks and changes in circumstances that are
difficult to predict. The Company's actual results may differ materially from
those contemplated by the forward-looking statements. The Company cautions you
therefore that you should not rely on any of these forward-looking statements as
statements of historical fact or as guarantees or assurances of future
performance. Important factors that could cause actual results to differ
materially from those in the forward-looking statements and regional, national,
global political, economic, business, competitive, market and regulatory
conditions.








This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.

Source: Summit Corporation PLC via Thomson Reuters ONE

[HUG#1559603]

Summit Corporation plc
("Summit" or "the Company")


EXERCISE OF WARRANTS

Oxford, UK, 27 September 2011, Summit (AIM: SUMM), a UK drug discovery company,
announces that it has issued 2,324,996 new Ordinary shares of 1.0 pence after
receiving payment of £116,249.80 following the partial exercise of Warrants held
by Singer Capital Markets ('Singer'), the Company's NOMAD and broker.

The Warrants were issued when Singer acted as lead broker on a Placing and Open
Offer ('the Fundraising'), which completed on 30 December 2009 following
approval from shareholders at a General Meeting of the Company.

The terms of the Warrants entitled Singer to subscribe for 3,324,996 Ordinary
shares of 1.0 pence at an exercise price of 5.0 pence per share at any time up
until 31 December 2013, the fourth anniversary of admission to trading of the
Fundraising shares.  This represented 2% of the Company's enlarged issued share
capital post completion of the Fundraising.  Following this exercise, Warrants
over 1,000,000 Ordinary shares remain outstanding.

Summit has applied for admission of the new Ordinary shares to trading on the
Alternative Investment Market of the London Stock Exchange ('Admission') and it
is expected that Admission will become effective on or around 30 September
2011.  The new Ordinary shares will rank pari passu with existing Ordinary
shares.  Following Admission, the Company will have 187,421,780 Ordinary shares
in issue.

- END -

For more information, please contact:

Summit

Barry Price, PhD,

Richard Pye, PhD Tel: +44 (0)1235 443 951



Singer Capital Markets (Nominated Adviser)

Shaun Dobson / Claes Spång Tel: +44 (0)20 3205 7500



Peckwater PR

Tarquin Edwards Tel: +44 (0)7879 458 364
tarquin.edwards@peckwaterpr.co.uk



Notes to Editors

About Summit
Summit is an Oxford, UK based drug discovery company with an innovative
technology platform called Seglins for the discovery of new medicines, a
portfolio of drug programme assets and a commercial strategy of signing multiple
early-stage deals.

Seglin(TM) technology is using new chemistry to access biological drug targets
that cannot be exploited by conventional drug discovery approaches.  Summit's
internal research is currently focussed in high-value therapy areas and the
Company will further exploit the technology's wider potential through strategic
alliances.  Summit's programme portfolio consists of a number of drug programmes
targeting high-value areas of unmet medical need including Duchenne Muscular
Dystrophy and C. difficile infection.

Summit's commercial strategy focuses on signing multiple early-stage drug
programme and technology platform deals that generate upfront cash, transfer
development costs from the Company, and retain valuable upside potential.

Summit is listed on the AIM market of the London Stock Exchange and trades under
the ticker symbol SUMM.  Further information is available at www.summitplc.com.


 Forward Looking Statements
This document contains "forward-looking statements" within the meaning of the
U.S. Private Securities Litigation Reform Act of 1995. Forward-looking
statements can be identified by words such as "anticipates", "intends", "plans",
"seeks", "believes", "estimates", "expects" and similar references to future
periods, or by the inclusion of forecasts or projections. Forward-looking
statements are based on the Company's current expectations and assumptions
regarding our business, the economy and other future conditions. Because
forward-looking statements relate to the future, by their nature, they are
subject to inherent uncertainties, risks and changes in circumstances that are
difficult to predict. The Company's actual results may differ materially from
those contemplated by the forward-looking statements. The Company cautions you
therefore that you should not rely on any of these forward-looking statements as
statements of historical fact or as guarantees or assurances of future
performance. Important factors that could cause actual results to differ
materially from those in the forward-looking statements and regional, national,
global political, economic, business, competitive, market and regulatory
conditions.








This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.

Source: Summit Corporation PLC via Thomson Reuters ONE

[HUG#1550027]